The Trump Conundrum: Republicans Will Run US Government, But Incoming President Is A Wildcard
Executive Summary
An underlying question is how well a President Trump will work with lawmakers in his own party, many of whom did not see eye to eye with the candidate at the top of their ticket during the campaign. There is also more uncertainty than usual about anticipated cabinet and agency appointments, such as for FDA and CMS, under the Trump administration.
You may also be interested in...
Trump's Triumph: Markets React, But 'Wait-And-See' Approach Advised For Medtech
Donald Trump's victory over Hillary Clinton in the US presidential election have sent many reeling in shock, but what impact has this had on health-care stocks the morning after, and what longer-term repercussions would a Trump administration have on the medtech industry?
Industry Gives Big Money To GOP Senators Backing Device Reforms, But Buys Into Clinton Over Trump, 14-1
In the 2016 election race, the most generous device and diagnostic industry contributors donated heavily to Senate Republicans giving legislative attention to FDA regulatory reforms – Richard Burr, N.C., Kelly Ayotte, N.H., Pat Toomey, Pa. – running close races against Democrat challengers. But while industry primarily backs GOP senators, they also favor Hillary Clinton (D) over Donald Trump (R) with their donations, 14-1.
Medtech In Politics: A Look At Republican And Democratic Party Platforms
The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.